{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["apoptosis", "cell invasion", "cell migration", "cytotoxicity", "natural products", "prostate cancer"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36826044", "DateRevised": {"Year": "2023", "Month": "02", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "02", "Day": "09"}], "Language": ["eng"], "ELocationID": ["10.3390/cimb45020099"], "Journal": {"ISSN": "1467-3045", "JournalIssue": {"Volume": "45", "Issue": "2", "PubDate": {"Year": "2023", "Month": "Feb", "Day": "09"}}, "Title": "Current issues in molecular biology", "ISOAbbreviation": "Curr Issues Mol Biol"}, "ArticleTitle": "Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia.", "Pagination": {"StartPage": "1536", "EndPage": "1567", "MedlinePgn": "1536-1567"}, "Abstract": {"AbstractText": ["Prostate cancer (PCa) remains both a global health burden and a scientific challenge. We present a review of the molecular targets driving current drug discovery to fight this disease. Moreover, the preventable nature of most PCa cases represents an opportunity for phytochemicals as chemopreventive when adequately integrated into nutritional interventions. With a renovated interest in natural remedies as a commodity and their essential role in cancer drug discovery, Malaysia is looking towards capitalizing on its mega biodiversity, which includes the oldest rainforest in the world and an estimated 1200 medicinal plants. We here explore whether the list of top Malay plants prioritized by the Malaysian government may fulfill the potential of becoming newer, sustainable sources of prostate cancer chemotherapy. These include <i>Andrographis paniculate, Centella asiatica, Clinacanthus nutans, Eurycoma longifolia, Ficus deltoidea, Hibiscus sabdariffa, Marantodes pumilum (</i>syn<i>. Labisia pumila), Morinda citrifolia, Orthosiphon aristatus,</i> and <i>Phyllanthus niruri</i>. Our review highlights the importance of resistance factors such as Smac/DIABLO in cancer progression, the role of the CXCL12/CXCR4 axis in cancer metastasis, and the regulation of PCa cells by some promising terpenes (andrographolide, Asiatic acid, rosmarinic acid), flavonoids (isovitexin, gossypin, sinensetin), and alkylresorcinols (labisiaquinones) among others."]}, "AuthorList": [{"Identifier": ["0000-0002-2649-1691"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University College London, London WC1N 1AX, UK."}, {"Identifier": [], "Affiliation": "School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK."}], "LastName": "Prieto", "ForeName": "Jose M", "Initials": "JM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, University College London, London WC1N 1AX, UK."}, {"Identifier": [], "Affiliation": "Institute of Bioproduct Development, Universiti Teknologi Malaysia, Skudai 81310, Malaysia."}], "LastName": "Hanafi", "ForeName": "Mohd Mukrish Mohd", "Initials": "MMM"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Curr Issues Mol Biol", "NlmUniqueID": "100931761", "ISSNLinking": "1467-3037"}, "CoiStatement": "The authors declare no conflict of interest. "}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Wang L., Lu B., He M., Wang Y., Wang Z., Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health. 2022;10:811044. doi: 10.3389/fpubh.2022.811044.", "ArticleIdList": ["10.3389/fpubh.2022.811044", "PMC8888523", "35252092"]}, {"Citation": "Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; Lyon, France: 2013."}, {"Citation": "Cancer Research UK  U.K. Prostate Cancer Statistics.  [(accessed on 16 February 2017)]; Available online:  http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero."}, {"Citation": "Institut Kanser Negara . Malaysia National Cancer Registry Report 2007. National Cancer Registry, M.o.H.M.; Kuala Lampur, Malaysia: 2011."}, {"Citation": "Wang M., Takahashi A., Liu F., Ye D., Ding Q., Qin C., Yin C., Zhang Z., Matsuda K., Kubo M., et al. Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. Nat. Commun. 2015;6:8469. doi: 10.1038/ncomms9469.", "ArticleIdList": ["10.1038/ncomms9469", "PMC4633711", "26443449"]}, {"Citation": "Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003;349:366\u2013381. doi: 10.1056/NEJMra021562.", "ArticleIdList": ["10.1056/NEJMra021562", "12878745"]}, {"Citation": "Liu M., Hai A., Huang A.T. Cancer epidemiology in the Far East--contrast with the United States. Oncology. 1993;6:99\u2013110.", "ArticleIdList": ["8318362"]}, {"Citation": "Wynder E.L., Fujita Y., Harris R.E., Hirayama T., Hiyama T. Comparative epidemiology of cancer between the united states and japan. A second look. Cancer. 1991;67:746\u2013763. doi: 10.1002/1097-0142(19910201)67:3<746::AID-CNCR2820670336>3.0.CO;2-1.", "ArticleIdList": ["10.1002/1097-0142(19910201)67:3<746::AID-CNCR2820670336>3.0.CO;2-1", "1985768"]}, {"Citation": "Nelson W.G., Demarzo A.M., Yegnasubramanian S. The diet as a cause of human prostate cancer. Cancer Treat. Res. 2014;159:51\u201368. doi: 10.1007/978-3-642-38007-5_4.", "ArticleIdList": ["10.1007/978-3-642-38007-5_4", "PMC4486067", "24114474"]}, {"Citation": "Sugimura T. Food and cancer. Toxicology. 2002;181\u2013182:17\u201321. doi: 10.1016/S0300-483X(02)00250-0.", "ArticleIdList": ["10.1016/S0300-483X(02)00250-0", "12505279"]}, {"Citation": "Coffey D.S. Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology. 2001;57:31\u201338. doi: 10.1016/S0090-4295(00)00938-9.", "ArticleIdList": ["10.1016/S0090-4295(00)00938-9", "11295592"]}, {"Citation": "Seethalakshmi L., Bala R.S., Malhotra R.K., Austin-Ritchie T., Miller-Graziano C., Menon M., Luber-Narod J. 17 beta-estradiol induced prostatitis in the rat is an autoimmune disease. J. Urol. 1996;156:1838\u20131842. doi: 10.1016/S0022-5347(01)65548-4.", "ArticleIdList": ["10.1016/S0022-5347(01)65548-4", "8863627"]}, {"Citation": "Pescatori S., Berardinelli F., Albanesi J., Ascenzi P., Marino M., Antoccia A., di Masi A., Acconcia F. A Tale of Ice and Fire: The Dual Role for 17\u03b2-Estradiol in Balancing DNA Damage and Genome Integrity. Cancers. 2021;13:1583. doi: 10.3390/cancers13071583.", "ArticleIdList": ["10.3390/cancers13071583", "PMC8036963", "33808099"]}, {"Citation": "Wu Y., Zhang L., Na R., Xu J., Xiong Z., Zhang N., Dai W., Jiang H., Ding Q. Plasma genistein and risk of prostate cancer in Chinese population. Int. Urol. Nephrol. 2015;47:965\u2013970. doi: 10.1007/s11255-015-0981-5.", "ArticleIdList": ["10.1007/s11255-015-0981-5", "PMC4445252", "25971353"]}, {"Citation": "Puangsombat K., Jirapakkul W., Smith J.S. Inhibitory Activity of Asian Spices on Heterocyclic Amines Formation in Cooked Beef Patties. J. Food Sci. 2011;76:T174\u2013T180. doi: 10.1111/j.1750-3841.2011.02338.x.", "ArticleIdList": ["10.1111/j.1750-3841.2011.02338.x", "21913920"]}, {"Citation": "Morrissey C., Watson R.W. Phytoestrogens and prostate cancer. Curr. Drug Targets. 2003;4:231\u2013241. doi: 10.2174/1389450033491154.", "ArticleIdList": ["10.2174/1389450033491154", "12643473"]}, {"Citation": "Christensen M.J., Quiner T.E., Nakken H.L., Lephart E.D., Eggett D.L., Urie P.M. Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer. Prostate. 2013;73:986\u2013995. doi: 10.1002/pros.22646.", "ArticleIdList": ["10.1002/pros.22646", "PMC4629493", "23389815"]}, {"Citation": "Hwang Y.W., Kim S.Y., Jee S.H., Kim Y.N., Nam C.M. Soy food consumption and risk of prostate cancer: A meta-analysis of observational studies. Nutr. Cancer. 2009;61:598\u2013606. doi: 10.1080/01635580902825639.", "ArticleIdList": ["10.1080/01635580902825639", "19838933"]}, {"Citation": "Sohel M., Sultana H., Sultana T., Mamun A.A., Amin M.N., Hossain M.A., Ali M.C., Aktar S., Sultana A., Rahim Z.B., et al. Chemotherapeutic Activities of Dietary Phytoestrogens against Prostate Cancer: From Observational to Clinical Studies. Curr. Pharm. Des. 2022;28:1561\u20131580. doi: 10.2174/1381612828666220601153426.", "ArticleIdList": ["10.2174/1381612828666220601153426", "35652403"]}, {"Citation": "Russo M., Russo G.L., Daglia M., Kasi P.D., Ravi S., Nabavi S.F., Nabavi S.M. Understanding genistein in cancer: The \"good\" and the \"bad\" effects: A review. Food Chem. 2016;196:589\u2013600. doi: 10.1016/j.foodchem.2015.09.085.", "ArticleIdList": ["10.1016/j.foodchem.2015.09.085", "26593532"]}, {"Citation": "Vastag B. Soy and Prostate Cancer Study Results Mixed. JNCI J. Natl. Cancer Inst. 2007;99:1364\u20131365. doi: 10.1093/jnci/djm162.", "ArticleIdList": ["10.1093/jnci/djm162", "17848664"]}, {"Citation": "Nupponen N., Visakorpi T. Molecular biology of progression of prostate cancer. Eur. Urol. 1999;35:351\u2013354. doi: 10.1159/000019907.", "ArticleIdList": ["10.1159/000019907", "10325488"]}, {"Citation": "Hughes C., Murphy A., Martin C., Sheils O., O\u2019Leary J. Molecular pathology of prostate cancer. J. Clin. Pathol. 2005;58:673. doi: 10.1136/jcp.2002.003954.", "ArticleIdList": ["10.1136/jcp.2002.003954", "PMC1770715", "15976331"]}, {"Citation": "Shi X., Sun M., Liu H., Yao Y., Song Y. Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett. 2013;339:159\u2013166. doi: 10.1016/j.canlet.2013.06.013.", "ArticleIdList": ["10.1016/j.canlet.2013.06.013", "23791884"]}, {"Citation": "Rubin C. The Genetic Basis of Human Cancer. Ann. Intern. Med. 1998;129:759. doi: 10.7326/0003-4819-129-9-199811010-00045.", "ArticleIdList": ["10.7326/0003-4819-129-9-199811010-00045"]}, {"Citation": "Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 2010;24:1967\u20132000. doi: 10.1101/gad.1965810.", "ArticleIdList": ["10.1101/gad.1965810", "PMC2939361", "20844012"]}, {"Citation": "Fraser M., Sabelnykova V.Y., Yamaguchi T.N., Heisler L.E., Livingstone J., Huang V., Shiah Y.-J., Yousif F., Lin X., Masella A.P., et al.  Genomic hallmarks of localized, non-indolent prostate cancer.  [(accessed on 30 July 2017)];Nature. 2017 541:359\u2013364. doi: 10.1038/nature20788. Available online:  http://www.nature.com/nature/journal/v541/n7637/abs/nature20788.html#supplementary-information.", "ArticleIdList": ["10.1038/nature20788", "28068672"]}, {"Citation": "Cher M.L., Bova G.S., Moore D.H., Small E.J., Carroll P.R., Pin S.S., Epstein J.I., Isaacs W.B., Jensen R.H. Genetic Alterations in Untreated Metastases and Androgen-independent Prostate Cancer Detected by Comparative Genomic Hybridization and Allelotyping. Cancer Res. 1996;56:3091\u20133102.", "ArticleIdList": ["8674067"]}, {"Citation": "Nupponen N.N., Kakkola L., Koivisto P., Visakorpi T. Genetic Alterations in Hormone-Refractory Recurrent Prostate Carcinomas. Am. J. Pathol. 1998;153:141\u2013148. doi: 10.1016/S0002-9440(10)65554-X.", "ArticleIdList": ["10.1016/S0002-9440(10)65554-X", "PMC1852946", "9665474"]}, {"Citation": "Visakorpi T., Kallioniemi A.H., Syv\u00e4nen A.-C., Hyytinen E.R., Karhu R., Tammela T., Isola J.J., Kallioniemi O.-P. Genetic Changes in Primary and Recurrent Prostate Cancer by Comparative Genomic Hybridization. Cancer Res. 1995;55:342\u2013347.", "ArticleIdList": ["7529134"]}, {"Citation": "Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11\u201322. doi: 10.1016/j.ccr.2010.05.026.", "ArticleIdList": ["10.1016/j.ccr.2010.05.026", "PMC3198787", "20579941"]}, {"Citation": "Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., Willi N., Mihatsch M.J., Sauter G., Kallioniemi O.-P. Survey of Gene Amplifications during Prostate Cancer Progression by High-Throughput Fluorescence in Situ Hybridization on Tissue Microarrays. Cancer Res. 1999;59:803\u2013806.", "ArticleIdList": ["10029066"]}, {"Citation": "Rickman D.S., Beltran H., Demichelis F., Rubin M.A. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 2017;23:664\u2013673. doi: 10.1038/nm.4341.", "ArticleIdList": ["10.1038/nm.4341", "28586335"]}, {"Citation": "Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., Guney I., Strochlic D.E., MacConaill L.E., Beroukhim R. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-[kappa] B. Nat. Med. 2010;16:286\u2013294. doi: 10.1038/nm.2100.", "ArticleIdList": ["10.1038/nm.2100", "PMC2903662", "20154697"]}, {"Citation": "Zeng X., Hu Z., Wang Z., Tao J., Lu T., Yang C., Lee B., Ye Z. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014;17:119\u2013125. doi: 10.1038/pcan.2013.51.", "ArticleIdList": ["10.1038/pcan.2013.51", "PMC4020276", "24418912"]}, {"Citation": "Morote J., de Torres I., Caceres C., Vallejo C., Schwartz S., Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int. J. Cancer. 1999;84:421\u2013425. doi: 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9.", "ArticleIdList": ["10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9", "10404097"]}, {"Citation": "Pignon J.-C., Koopmansch B., Nolens G., Delacroix L., Waltregny D., Winkler R. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res. 2009;69:2941\u20132949. doi: 10.1158/0008-5472.CAN-08-3760.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-3760", "19318561"]}, {"Citation": "Yan M., Parker B.A., Schwab R., Kurzrock R. HER2 aberrations in cancer: Implications for therapy. Cancer Treat. Rev. 2014;40:770\u2013780. doi: 10.1016/j.ctrv.2014.02.008.", "ArticleIdList": ["10.1016/j.ctrv.2014.02.008", "24656976"]}, {"Citation": "Colombel M., Symmans F., Gil S., O\u2019Toole K.M., Chopin D., Benson M., Olsson C.A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 1993;143:390\u2013400.", "ArticleIdList": ["PMC1887010", "7688182"]}, {"Citation": "Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J.C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 1996;148:1567\u20131576.", "ArticleIdList": ["PMC1861561", "8623925"]}, {"Citation": "McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W.K., Hsieh J.-T., Tu S.-M., Campbell M.L. Expression of the Protooncogene bcl-2 in the Prostate and Its Association with Emergence of Androgen-independent Prostate Cancer. Cancer Res. 1992;52:6940\u20136944.", "ArticleIdList": ["1458483"]}, {"Citation": "Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006;12:1665\u20131671. doi: 10.1158/1078-0432.CCR-06-0067.", "ArticleIdList": ["10.1158/1078-0432.CCR-06-0067", "16551847"]}, {"Citation": "Delbridge A.R.D., Grabow S., Strasser A., Vaux D.L. Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer. 2016;16:99\u2013109. doi: 10.1038/nrc.2015.17.", "ArticleIdList": ["10.1038/nrc.2015.17", "26822577"]}, {"Citation": "Velcheti V., Karnik S., Bardot S.F., Prakash O. Pathogenesis of Prostate Cancer: Lessons from Basic Research. Ochsner J. 2008;8:213\u2013218.", "ArticleIdList": ["PMC3096366", "21603505"]}, {"Citation": "Edwards J., Bartlett J. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int. 2005;95:1327\u20131335. doi: 10.1111/j.1464-410X.2005.05527.x.", "ArticleIdList": ["10.1111/j.1464-410X.2005.05527.x", "15892826"]}, {"Citation": "Chmelar R., Buchanan G., Need E.F., Tilley W., Greenberg N.M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer. 2007;120:719\u2013733. doi: 10.1002/ijc.22365.", "ArticleIdList": ["10.1002/ijc.22365", "17163421"]}, {"Citation": "Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996;28:251\u2013265. doi: 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G.", "ArticleIdList": ["10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G", "8602401"]}, {"Citation": "Tan M.H.E., Li J., Xu H.E., Melcher K., Yong E.-l. Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 2015;36:3\u201323. doi: 10.1038/aps.2014.18.", "ArticleIdList": ["10.1038/aps.2014.18", "PMC4571323", "24909511"]}, {"Citation": "Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005;23:8253\u20138261. doi: 10.1200/JCO.2005.03.4777.", "ArticleIdList": ["10.1200/JCO.2005.03.4777", "16278481"]}, {"Citation": "Roudier M.P., Morrissey C., True L.D., Higano C.S., Vessella R.L., Ott S.M. Histopathological assessment of prostate cancer bone osteoblastic metastases. J. Urol. 2008;180:1154\u20131160. doi: 10.1016/j.juro.2008.04.140.", "ArticleIdList": ["10.1016/j.juro.2008.04.140", "PMC2992811", "18639279"]}, {"Citation": "Rubens R. Bone metastases\u2014The clinical problem. Eur. J. Cancer. 1998;34:210\u2013213. doi: 10.1016/S0959-8049(97)10128-9.", "ArticleIdList": ["10.1016/S0959-8049(97)10128-9", "9741323"]}, {"Citation": "Fizazi K., Carducci M., Smith M., Dami\u00e3o R., Brown J., Karsh L., Milecki P., Shore N., Rader M., Wang H., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377:813\u2013822. doi: 10.1016/S0140-6736(10)62344-6.", "ArticleIdList": ["10.1016/S0140-6736(10)62344-6", "PMC3090685", "21353695"]}, {"Citation": "Geldof A. Models for cancer skeletal metastasis: A reappraisal of Batson\u2019s plexus. Anticancer Res. 1996;17:1535\u20131539.", "ArticleIdList": ["9179192"]}, {"Citation": "Diel I. Metastatic Bone Disease. Springer; Berlin/Heidelberg, Germany: 1994. Historical remarks on metastasis and metastatic bone disease; pp. 1\u201311."}, {"Citation": "Kim C.H., Broxmeyer H.E. SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: Differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation. J. Leukoc. Biol. 1999;66:455\u2013461. doi: 10.1002/jlb.66.3.455.", "ArticleIdList": ["10.1002/jlb.66.3.455", "10496316"]}, {"Citation": "Aiuti A., Tavian M., Cipponi A., Ficara F., Zappone E., Hoxie J., Peault B., Bordignon C. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lymphohematopoietic progenitors. Eur. J. Immunol. 1999;29:1823\u20131831. doi: 10.1002/(SICI)1521-4141(199906)29:06<1823::AID-IMMU1823>3.0.CO;2-B.", "ArticleIdList": ["10.1002/(SICI)1521-4141(199906)29:06<1823::AID-IMMU1823>3.0.CO;2-B", "10382744"]}, {"Citation": "Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the Stromal Cell-derived Factor-1/CXCR4 Pathway in Prostate Cancer Metastasis to Bone. Cancer Res. 2002;62:1832.", "ArticleIdList": ["11912162"]}, {"Citation": "Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., Pienta K.J., Taichman R.S. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell. Biochem. 2003;89:462\u2013473. doi: 10.1002/jcb.10522.", "ArticleIdList": ["10.1002/jcb.10522", "12761880"]}, {"Citation": "M\u00fcller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50\u201356. doi: 10.1038/35065016.", "ArticleIdList": ["10.1038/35065016", "11242036"]}, {"Citation": "Morton R.A., Ewing C.M., Nagafuchi A., Tsukita S., Isaacs W.B. Reduction of E-Cadherin Levels and Deletion of the \u03b1-Catenin Gene in Human Prostate Cancer Cells. Cancer Res. 1993;53:3585\u20133590.", "ArticleIdList": ["8339265"]}, {"Citation": "Umbas R., Schalken J.A., Aalders T.W., Carter B.S., Karthaus H.F.M., Schaafsma H.K., Debruyne F.M.J., Isaacs W.B. Expression of the Cellular Adhesion Molecule E-Cadherin Is Reduced or Absent in High-Grade Prostate Cancer. Cancer Res. 1992;52:5104\u20135109.", "ArticleIdList": ["1516067"]}, {"Citation": "Mashimo T., Watabe M., Hirota S., Hosobe S., Miura K., Tegtmeyer P.J., Rinker-Shaeffer C.W., Watabe K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl. Acad. Sci. USA. 1998;95:11307\u201311311. doi: 10.1073/pnas.95.19.11307.", "ArticleIdList": ["10.1073/pnas.95.19.11307", "PMC21638", "9736732"]}, {"Citation": "Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K.-i., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998;58:3761\u20133764.", "ArticleIdList": ["9731479"]}, {"Citation": "Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987\u2013990.", "ArticleIdList": ["10070951"]}, {"Citation": "Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006;71:1397\u20131421. doi: 10.1016/j.bcp.2006.02.009.", "ArticleIdList": ["10.1016/j.bcp.2006.02.009", "16563357"]}, {"Citation": "Wolfesberger B., Walter I., Hoelzl C., Thalhammer J.G., Egerbacher M. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res. Vet. Sci. 2006;80:308\u2013316. doi: 10.1016/j.rvsc.2005.07.013.", "ArticleIdList": ["10.1016/j.rvsc.2005.07.013", "16182328"]}, {"Citation": "Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., Dubois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183\u20131188. doi: 10.1016/0016-5085(94)90246-1.", "ArticleIdList": ["10.1016/0016-5085(94)90246-1", "7926468"]}, {"Citation": "Koga H., Sakisaka S., Ohishi M., Kawaguchi T., Taniguchi E., Sasatomi K., Harada M., Kusaba T., Tanaka M., Kimura R. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology. 1999;29:688\u2013696. doi: 10.1002/hep.510290355.", "ArticleIdList": ["10.1002/hep.510290355", "10051469"]}, {"Citation": "Hwang D., Byrne J., Scollard D., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 1998;90:455\u2013460. doi: 10.1093/jnci/90.6.455.", "ArticleIdList": ["10.1093/jnci/90.6.455", "9521170"]}, {"Citation": "Mohammed S.I., Knapp D.W., Bostwick D.G., Foster R.S., Khan K.N.M., Masferrer J.L., Woerner B.M., Snyder P.W., Koki A.T. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 1999;59:5647\u20135650.", "ArticleIdList": ["10582676"]}, {"Citation": "Ghosh J., Myers C.E. Arachidonic Acid Stimulates Prostate Cancer Cell Growth: Critical Role of 5-Lipoxygenase. Biochem. Biophys. Res. Commun. 1997;235:418\u2013423. doi: 10.1006/bbrc.1997.6799.", "ArticleIdList": ["10.1006/bbrc.1997.6799", "9199209"]}, {"Citation": "Yang P., Cartwright C.A., Li J.I.N., Wen S., Prokhorova I.N., Shureiqi I., Troncoso P., Navone N.M., Newman R.A., Kim J. Arachidonic acid metabolism in human prostate cancer. Int. J. Oncol. 2012;41:1495\u20131503. doi: 10.3892/ijo.2012.1588.", "ArticleIdList": ["10.3892/ijo.2012.1588", "PMC3982713", "22895552"]}, {"Citation": "Werz O., Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006;112:701\u2013718. doi: 10.1016/j.pharmthera.2006.05.009.", "ArticleIdList": ["10.1016/j.pharmthera.2006.05.009", "16837050"]}, {"Citation": "R\u00e5dmark O., Werz O., Steinhilber D., Samuelsson B. 5-Lipoxygenase: Regulation of expression and enzyme activity. Trends Biochem. Sci. 2007;32:332\u2013341. doi: 10.1016/j.tibs.2007.06.002.", "ArticleIdList": ["10.1016/j.tibs.2007.06.002", "17576065"]}, {"Citation": "F\u00fcrstenberger G., Krieg P., M\u00fcller-Decker K., Habenicht A.J.R. What are cyclooxygenases and lipoxygenases doing in the driver\u2019s seat of carcinogenesis? Int. J. Cancer. 2006;119:2247\u20132254. doi: 10.1002/ijc.22153.", "ArticleIdList": ["10.1002/ijc.22153", "16921484"]}, {"Citation": "Ghosh J. Targeting 5-lipoxygenase for prevention and treatment of cancer. Curr. Enzym. Inhib. 2008;4:18\u201328. doi: 10.2174/157340808783502540.", "ArticleIdList": ["10.2174/157340808783502540"]}, {"Citation": "Holmgren L., O\u2019Reilly M.S., Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995;1:149\u2013153. doi: 10.1038/nm0295-149.", "ArticleIdList": ["10.1038/nm0295-149", "7585012"]}, {"Citation": "Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003;9:653\u2013660. doi: 10.1038/nm0603-653.", "ArticleIdList": ["10.1038/nm0603-653", "12778163"]}, {"Citation": "Li R., Younes M., Wheeler T.M., Scardino P., Ohori M., Frolov A., Ayala G. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate. 2004;58:193\u2013199. doi: 10.1002/pros.10321.", "ArticleIdList": ["10.1002/pros.10321", "14716745"]}, {"Citation": "Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003;9:669\u2013676. doi: 10.1038/nm0603-669.", "ArticleIdList": ["10.1038/nm0603-669", "12778165"]}, {"Citation": "Friesel R.E., Maciag T. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J. 1995;9:919\u2013925. doi: 10.1096/fasebj.9.10.7542215.", "ArticleIdList": ["10.1096/fasebj.9.10.7542215", "7542215"]}, {"Citation": "Battegay E.J., Rupp J., Iruela-Arispe L., Sage E.H., Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J. Cell Biol. 1994;125:917\u2013928. doi: 10.1083/jcb.125.4.917.", "ArticleIdList": ["10.1083/jcb.125.4.917", "PMC2120083", "7514607"]}, {"Citation": "Wang B., Hendricks D.T., Wamunyokoli F., Parker M.I. A Growth-Related Oncogene/CXC Chemokine Receptor 2 Autocrine Loop Contributes to Cellular Proliferation in Esophageal Cancer. Cancer Res. 2006;66:3071\u20133077. doi: 10.1158/0008-5472.CAN-05-2871.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-2871", "16540656"]}, {"Citation": "Sankar S., Mahooti-Brooks N., Bensen L., McCarthy T.L., Centrella M., Madri J.A. Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. J. Clin. Investig. 1996;97:1436\u20131446. doi: 10.1172/JCI118565.", "ArticleIdList": ["10.1172/JCI118565", "PMC507203", "8617876"]}, {"Citation": "Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2002;2:161\u2013174. doi: 10.1038/nrc745.", "ArticleIdList": ["10.1038/nrc745", "11990853"]}, {"Citation": "He Y., Kozaki K.-i., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., Alitalo K. Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling. J. Natl. Cancer Inst. 2002;94:819\u2013825. doi: 10.1093/jnci/94.11.819.", "ArticleIdList": ["10.1093/jnci/94.11.819", "12048269"]}, {"Citation": "Murphy G., Ragde H., Kenny G., Barren R., 3rd, Erickson S., Tjoa B., Boynton A., Holmes E., Gilbaugh J., Douglas T. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 1995;15:1473\u20131479.", "ArticleIdList": ["7544569"]}, {"Citation": "Chang S.S., Heston W.D. The clinical role of prostate-specific membrane antigen (PSMA) Urol. Oncol. 2002;7:7\u201312. doi: 10.1016/S1078-1439(01)00124-7.", "ArticleIdList": ["10.1016/S1078-1439(01)00124-7", "12474535"]}, {"Citation": "Conway R.E., Petrovic N., Li Z., Heston W., Wu D., Shapiro L.H. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol. Cell Biol. 2006;26:5310\u20135324. doi: 10.1128/MCB.00084-06.", "ArticleIdList": ["10.1128/MCB.00084-06", "PMC1592718", "16809768"]}, {"Citation": "Gao Y., Zheng H., Li L., Feng M., Chen X., Hao B., Lv Z., Zhou X., Cao Y. Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-\u03baB Signaling Pathway. Front. Cell Dev. Biol. 2021;9:598377. doi: 10.3389/fcell.2021.598377.", "ArticleIdList": ["10.3389/fcell.2021.598377", "PMC7969793", "33748101"]}, {"Citation": "Bradbury R., Jiang W.G., Cui Y.-X. The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers. Biomark. Med. 2015;9:1353\u20131370. doi: 10.2217/bmm.15.94.", "ArticleIdList": ["10.2217/bmm.15.94", "26581688"]}, {"Citation": "Watanabe R., Maekawa M., Kiyoi T., Kurata M., Miura N., Kikugawa T., Higashiyama S., Saika T. PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state. Prostate. 2021;81:1390\u20131401. doi: 10.1002/pros.24237.", "ArticleIdList": ["10.1002/pros.24237", "PMC9292811", "34516672"]}, {"Citation": "Machado C.M.L., Skubal M., Haedicke K., Silva F.P., Stater E.P., de Oliveira Silva T.L.A., Costa E.T., Masotti C., Otake A.H., Andrade L.N.S., et al. PSMA-bearing extracellular vesicles secreted from prostate cancer convert the microenvironment to a tumor-supporting, pro-angiogenic state. bioRxiv. 2022:2022-02. doi: 10.1101/2022.02.25.482024.", "ArticleIdList": ["10.1101/2022.02.25.482024"]}, {"Citation": "Brawley O.W. The Potential for Prostate Cancer Chemoprevention. Rev. Urol. 2002;4:S11\u2013S17. doi: 10.1093/oxfordjournals.epirev.a000785.", "ArticleIdList": ["10.1093/oxfordjournals.epirev.a000785", "PMC1476013", "16986061"]}, {"Citation": "Sporn M.B., Newton D.L. Federation Proceedings. Federation of American Societies for Experimental Biology; Rockville, MD, USA: 1979. Chemoprevention of cancer with retinoids; pp. 2528\u20132534.", "ArticleIdList": ["488376"]}, {"Citation": "Kelloff G.J., Lieberman R., Steele V.E., Boone C.W., Lubet R.A., Kopelovitch L., Malone W.A., Crowell J.A., Sigman C.C. Chemoprevention of prostate cancer: Concepts and strategies. Eur. Urol. 1999;35:342\u2013350. doi: 10.1159/000019906.", "ArticleIdList": ["10.1159/000019906", "10325487"]}, {"Citation": "Sandhu G.S., Nepple K.G., Tanagho Y.S., Andriole G.L. Seminars in Oncology. WB Saunders; Philadelphia, PA, USA: 2013. Prostate cancer chemoprevention; pp. 276\u2013285.", "ArticleIdList": ["23806493"]}, {"Citation": "Gonzalgo M.L., Isaacs W.B. Molecular pathways to prostate cancer. J. Urol. 2003;170:2444\u20132452. doi: 10.1097/01.ju.0000085381.20139.b6.", "ArticleIdList": ["10.1097/01.ju.0000085381.20139.b6", "14634448"]}, {"Citation": "Epstein J.I., Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J. Urol. 2006;175:820\u2013834. doi: 10.1016/S0022-5347(05)00337-X.", "ArticleIdList": ["10.1016/S0022-5347(05)00337-X", "16469560"]}, {"Citation": "Stamatiou K., Alevizos A., Agapitos E., Sofras F. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: An autopsy study. Prostate. 2006;66:1319\u20131328. doi: 10.1002/pros.20339.", "ArticleIdList": ["10.1002/pros.20339", "16688747"]}, {"Citation": "Hong W.K., Lippman S.M. Cancer chemoprevention. J. Natl. Cancer Inst. Monogr. 1994;12:49\u201353.", "ArticleIdList": ["8573453"]}, {"Citation": "Walsh P.C. Chemoprevention of prostate cancer. N. Engl. J. Med. 2010;362:1237\u20131238. doi: 10.1056/NEJMe1001045.", "ArticleIdList": ["10.1056/NEJMe1001045", "20357287"]}, {"Citation": "Tsukamoto S., Akaza H., Onozawa M., Shirai T., Ideyama Y. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer. 1998;82:531\u2013537. doi: 10.1002/(SICI)1097-0142(19980201)82:3<531::AID-CNCR15>3.0.CO;2-2.", "ArticleIdList": ["10.1002/(SICI)1097-0142(19980201)82:3<531::AID-CNCR15>3.0.CO;2-2", "9452271"]}, {"Citation": "Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., Melman A., Bracken R.B., deVere White R., Taylor A. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo. Urology. 1999;54:662\u2013669. doi: 10.1016/S0090-4295(99)00232-0.", "ArticleIdList": ["10.1016/S0090-4295(99)00232-0", "10510925"]}, {"Citation": "Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43:284\u2013294. doi: 10.1016/0090-4295(94)90068-X.", "ArticleIdList": ["10.1016/0090-4295(94)90068-X", "7510911"]}, {"Citation": "Bramson H.N., Hermann D., Batchelor K.W., Lee F.W., James M.K., Frye S.V. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J. Pharmacol. Exp. Ther. 1997;282:1496\u20131502.", "ArticleIdList": ["9316864"]}, {"Citation": "Andriole G.L., Bostwick D.G., Brawley O.W., Gomella L.G., Marberger M., Montorsi F., Pettaway C.A., Tammela T.L., Teloken C., Tindall D.J., et al. Effect of Dutasteride on the Risk of Prostate Cancer. N. Engl. J. Med. 2010;362:1192\u20131202. doi: 10.1056/NEJMoa0908127.", "ArticleIdList": ["10.1056/NEJMoa0908127", "20357281"]}, {"Citation": "Lu-Yao G.L., Albertsen P.C., Moore D.F., Shih W., Lin Y., DiPaola R.S., Barry M.J., Zietman A., O\u2019Leary M., Walker-Corkery E., et al. Outcomes of Localized Prostate Cancer Following Conservative Management. JAMA J. Am. Med. Assoc. 2009;302:1202\u20131209. doi: 10.1001/jama.2009.1348.", "ArticleIdList": ["10.1001/jama.2009.1348", "PMC2822438", "19755699"]}, {"Citation": "Mongiat-Artus P., Peyromaure M., Richaud P., Droz J.P., Rainfray M., Jeandel C., Rebillard X., Moreau J.L., Davin J.L., Salomon L., et al. Recommandations pour la prise en charge du cancer de la prostate chez l\u2019homme \u00e2g\u00e9: Un travail du comit\u00e9 de canc\u00e9rologie de l\u2019association fran\u00e7aise d\u2019urologie. Progr\u00e8s En Urol. 2009;19:810\u2013817. doi: 10.1016/j.purol.2009.02.008.", "ArticleIdList": ["10.1016/j.purol.2009.02.008", "19945664"]}, {"Citation": "Picard J.C., Golshayan A.-R., Marshall D.T., Opfermann K.J., Keane T.E. The multi-disciplinary management of high-risk prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2012;30:3\u201315. doi: 10.1016/j.urolonc.2009.09.002.", "ArticleIdList": ["10.1016/j.urolonc.2009.09.002", "19945310"]}, {"Citation": "Pound C. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. JAMA J. Am. Med. Assoc. 1999;281:1591. doi: 10.1001/jama.281.17.1591.", "ArticleIdList": ["10.1001/jama.281.17.1591", "10235151"]}, {"Citation": "Uchio E. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. Arch. Intern. Med. 2010;170:1390. doi: 10.1001/archinternmed.2010.262.", "ArticleIdList": ["10.1001/archinternmed.2010.262", "20696967"]}, {"Citation": "Antonarakis E., Trock B., Feng Z., Humphreys E., Carducci M., Partin A., Walsh P., Eisenberger M. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J. Clin. Oncol. 2009;27((Suppl. S15)):5008. doi: 10.1200/jco.2009.27.15_suppl.5008.", "ArticleIdList": ["10.1200/jco.2009.27.15_suppl.5008", "0"]}, {"Citation": "D\u2019Amico A., Cote K., Loffredo M., Renshaw A., Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J. Clin. Oncol. 2002;20:4567\u20134573. doi: 10.1200/JCO.2002.03.061.", "ArticleIdList": ["10.1200/JCO.2002.03.061", "12454114"]}, {"Citation": "Paller C.J., Antonarakis E.S. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Dev. Ther. 2011;5:117\u2013124. doi: 10.2147/DDDT.S13029.", "ArticleIdList": ["10.2147/DDDT.S13029", "PMC3063116", "21448449"]}, {"Citation": "Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., Armitage G.R., Wilson J.J., Venner P.M., Coppin C.M., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996;14:1756\u20131764. doi: 10.1200/JCO.1996.14.6.1756.", "ArticleIdList": ["10.1200/JCO.1996.14.6.1756", "8656243"]}, {"Citation": "Petrylak D., Petrylak C., Tangen M.H.A., Hussain P., Lara J., Jones M., Taplin P., Burch D., Berry C., Moinpour M., et al. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. N. Engl. J. Med. 2004;351:1513\u20131520. doi: 10.1056/NEJMoa041318.", "ArticleIdList": ["10.1056/NEJMoa041318", "15470214"]}, {"Citation": "Fiorica F., Buttigliero C., Grigolato D., Muraro M., Turco F., Munoz F., Tucci M. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. Curr. Oncol. 2022;29:9511\u20139524. doi: 10.3390/curroncol29120747.", "ArticleIdList": ["10.3390/curroncol29120747", "PMC9776703", "36547161"]}, {"Citation": "D\u2019Aniello C., Cavaliere C., Foglia C., Facchini S., Uricchio F., Balsamo R., Franzese E., De Falco S., Izzo M., Laterza M., et al. Management of systemic prostate cancer: Current algorithm from castration sensitive to castration resistant setting. Eur. Rev. Med. Pharmacol. Sci. 2022;26:8481\u20138501. doi: 10.26355/eurrev_202211_30384.", "ArticleIdList": ["10.26355/eurrev_202211_30384", "36459030"]}, {"Citation": "Pozas J., \u00c1lvarez Rodr\u00edguez S., Fern\u00e1ndez V.A., Burgos J., Santoni M., Manneh Kopp R., Molina-Cerrillo J., Alonso-Gordoa T. Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future? Cancers. 2022;14:6071. doi: 10.3390/cancers14246071.", "ArticleIdList": ["10.3390/cancers14246071", "PMC9776956", "36551557"]}, {"Citation": "Chen K., O\u2019Brien J., McVey A., Jenjitranant P., Kelly B.D., Kasivisvanathan V., Lawrentschuk N., Murphy D.G., Azad A.A. Combination treatment in metastatic prostate cancer: Is the bar too high or have we fallen short? Nat. Rev. Urol. 2022;20:116\u2013123. doi: 10.1038/s41585-022-00669-z.", "ArticleIdList": ["10.1038/s41585-022-00669-z", "36509970"]}, {"Citation": "Higano C.S., Hafron J. Adherence with Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences with a Focus on Prostate Cancer. J. Urol. 2022;209:10\u20131097. doi: 10.1097/JU.0000000000003081.", "ArticleIdList": ["10.1097/JU.0000000000003081", "36472138"]}, {"Citation": "Klose P., Werner M., Saha F., Voi\u00df P. Mind-body medicine in integrative uro-oncology: Studies and areas of application. Urologie. 2022;62:27\u201333. doi: 10.1007/s00120-022-01978-2.", "ArticleIdList": ["10.1007/s00120-022-01978-2", "36471013"]}, {"Citation": "Kumar R., Sena L.A., Denmeade S.R., Kachhap S. The testosterone paradox of advanced prostate cancer: Mechanistic insights and clinical implications. Nat. Rev. Urol. 2022:1\u201314. doi: 10.1038/s41585-022-00686-y.", "ArticleIdList": ["10.1038/s41585-022-00686-y", "36543976"]}, {"Citation": "Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000;100:57\u201370. doi: 10.1016/S0092-8674(00)81683-9.", "ArticleIdList": ["10.1016/S0092-8674(00)81683-9", "10647931"]}, {"Citation": "Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Blandin A.-F., Renner G., Lehmann M., Lelong-Rebel I., Martin S., Dontenwill M. \u03b21 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Front. Pharmacol. 2015;6:279. doi: 10.3389/fphar.2015.00279.", "ArticleIdList": ["10.3389/fphar.2015.00279", "PMC4656837", "26635609"]}, {"Citation": "Vaux D.L., Korsmeyer S.J. Cell death in development. Cell. 1999;96:245\u2013254. doi: 10.1016/S0092-8674(00)80564-4.", "ArticleIdList": ["10.1016/S0092-8674(00)80564-4", "9988219"]}, {"Citation": "Martinez-Ruiz G., Maldonado V., Ceballos-Cancino G., Grajeda J.P.R., Melendez-Zajgla J. Role of Smac/DIABLO in cancer progression. J. Exp. Clin. Cancer Res. CR. 2008;27:48. doi: 10.1186/1756-9966-27-48.", "ArticleIdList": ["10.1186/1756-9966-27-48", "PMC2566557", "18822137"]}, {"Citation": "Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems. Exp. Cell Res. 2000;256:58\u201366. doi: 10.1006/excr.2000.4840.", "ArticleIdList": ["10.1006/excr.2000.4840", "10739652"]}, {"Citation": "Fulda S., Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798\u20134811. doi: 10.1038/sj.onc.1209608.", "ArticleIdList": ["10.1038/sj.onc.1209608", "16892092"]}, {"Citation": "Green D.R., Kroemer G. The Pathophysiology of Mitochondrial Cell Death. Science. 2004;305:626. doi: 10.1126/science.1099320.", "ArticleIdList": ["10.1126/science.1099320", "15286356"]}, {"Citation": "Cand\u00e9 C., Cecconi F., Dessen P., Kroemer G. Apoptosis-inducing factor (AIF): Key to the conserved caspase-independent pathways of cell death? J. Cell Sci. 2002;115:4727. doi: 10.1242/jcs.00210.", "ArticleIdList": ["10.1242/jcs.00210", "12432061"]}, {"Citation": "Saelens X., Festjens N., Walle L.V., Van Gurp M., van Loo G., Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23:2861\u20132874. doi: 10.1038/sj.onc.1207523.", "ArticleIdList": ["10.1038/sj.onc.1207523", "15077149"]}, {"Citation": "Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c\u2013dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33\u201342. doi: 10.1016/S0092-8674(00)00008-8.", "ArticleIdList": ["10.1016/S0092-8674(00)00008-8", "10929711"]}, {"Citation": "Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43\u201353. doi: 10.1016/S0092-8674(00)00009-X.", "ArticleIdList": ["10.1016/S0092-8674(00)00009-X", "10929712"]}, {"Citation": "Jia L., Patwari Y., Kelsey S.M., Srinivasula S.M., Agrawal S.G., Alnemri E.S., Newland A.C. Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene. 2003;22:1589\u20131599. doi: 10.1038/sj.onc.1206322.", "ArticleIdList": ["10.1038/sj.onc.1206322", "12642862"]}, {"Citation": "Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215\u20132223. doi: 10.1093/emboj/17.8.2215.", "ArticleIdList": ["10.1093/emboj/17.8.2215", "PMC1170566", "9545235"]}, {"Citation": "Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., Lee R.-A., Robbins P.D., Fernandes-Alnemri T., Shi Y. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410:112\u2013116. doi: 10.1038/35065125.", "ArticleIdList": ["10.1038/35065125", "11242052"]}, {"Citation": "Carson J.P., Behnam M., Sutton J.N., Du C., Wang X., Hunt D.F., Weber M.J., Kulik G. Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. Cancer Res. 2002;62:18\u201323.", "ArticleIdList": ["11782351"]}, {"Citation": "Guo F., Nimmanapalli R., Paranawithana S., Wittman S., Griffin D., Bali P., O\u2019Bryan E., Fumero C., Wang H.G., Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative\u2013(BMS 247550) and Apo-2L/TRAIL\u2013induced apoptosis. Blood. 2002;99:3419\u20133426. doi: 10.1182/blood.V99.9.3419.", "ArticleIdList": ["10.1182/blood.V99.9.3419", "11964312"]}, {"Citation": "Fulda S., Wick W., Weller M., Debatin K.-M. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002;8:808\u2013815. doi: 10.1038/nm735.", "ArticleIdList": ["10.1038/nm735", "12118245"]}, {"Citation": "Perimenis P., Galaris A., Voulgari A., Prassa M., Pintzas A. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer. 2016;16:624. doi: 10.1186/s12885-016-2606-5.", "ArticleIdList": ["10.1186/s12885-016-2606-5", "PMC4982265", "27520705"]}, {"Citation": "Chinni S.R., Sivalogan S., Dong Z., Deng X., Bonfil R.D., Cher M.L. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate. 2006;66:32\u201348. doi: 10.1002/pros.20318.", "ArticleIdList": ["10.1002/pros.20318", "16114056"]}, {"Citation": "Singareddy R., Semaan L., Conley-LaComb M.K., John J.S., Powell K., Iyer M., Smith D., Heilbrun L.K., Shi D., Sakr W. Transcriptional regulation of CXCR4 in prostate cancer: Significance of TMPRSS2-ERG fusions. Mol. Cancer Res. 2013;11:1349\u20131361. doi: 10.1158/1541-7786.MCR-12-0705.", "ArticleIdList": ["10.1158/1541-7786.MCR-12-0705", "PMC3901058", "23918819"]}, {"Citation": "Conley-LaComb M.K., Saliganan A., Kandagatla P., Chen Y.Q., Cher M.L., Chinni S.R. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol. Cancer. 2013;12:85. doi: 10.1186/1476-4598-12-85.", "ArticleIdList": ["10.1186/1476-4598-12-85", "PMC3751767", "23902739"]}, {"Citation": "Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., Taichman R.S., Pienta K.J., Wang J. CXCL12/CXCR4/CXCR7 Chemokine Axis and Cancer Progression. Cancer Metastasis Rev. 2010;29:709\u2013722. doi: 10.1007/s10555-010-9256-x.", "ArticleIdList": ["10.1007/s10555-010-9256-x", "PMC3175097", "20839032"]}, {"Citation": "Vindrieux D., Escobar P., Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr.-Relat. Cancer. 2009;16:663\u2013673. doi: 10.1677/ERC-09-0109.", "ArticleIdList": ["10.1677/ERC-09-0109", "19556286"]}, {"Citation": "Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2001;2:129\u2013134. doi: 10.1038/84224.", "ArticleIdList": ["10.1038/84224", "11175805"]}, {"Citation": "Gillette J.M., Larochelle A., Dunbar C.E., Lippincott-Schwartz J. Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nat. Cell Biol. 2009;11:303\u2013311. doi: 10.1038/ncb1838.", "ArticleIdList": ["10.1038/ncb1838", "PMC2748410", "19198600"]}, {"Citation": "Kyriakou C., Rabin N., Pizzey A., Nathwani A., Yong K. Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica. 2008;93:1457\u20131465. doi: 10.3324/haematol.12553.", "ArticleIdList": ["10.3324/haematol.12553", "18728032"]}, {"Citation": "Sun Y.X., Schneider A., Jung Y., Wang J., Dai J., Wang J., Cook K., Osman N.I., Koh-Paige A.J., Shim H. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 2005;20:318\u2013329. doi: 10.1359/JBMR.041109.", "ArticleIdList": ["10.1359/JBMR.041109", "15647826"]}, {"Citation": "Engl T., Relja B., Marian D., Blumenberg C., M\u00fcller I., Beecken W.-D., Jones J., Ringel E.M., Bereiter-Hahn J., Jonas D. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through \u03b15 and \u03b23 integrins. Neoplasia. 2006;8:290\u2013301. doi: 10.1593/neo.05694.", "ArticleIdList": ["10.1593/neo.05694", "PMC1600676", "16756721"]}, {"Citation": "Lee J.Y., Kang D.H., Chung D.Y., Kwon J.K., Lee H., Cho N.H., Choi Y.D., Hong S.J., Cho K.S. Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer. World J. Men\u2019s Health. 2014;32:167\u2013175. doi: 10.5534/wjmh.2014.32.3.167.", "ArticleIdList": ["10.5534/wjmh.2014.32.3.167", "PMC4298820", "25606566"]}, {"Citation": "Folkman J. What is the evidence that tumors are angiogenesis dependent? CancerSpectrum Knowl. Environ. 1990;82:4\u20136. doi: 10.1093/jnci/82.1.4.", "ArticleIdList": ["10.1093/jnci/82.1.4", "1688381"]}, {"Citation": "Ferrara N., Hillan K.J., Gerber H.-P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004;3:391\u2013400. doi: 10.1038/nrd1381.", "ArticleIdList": ["10.1038/nrd1381", "15136787"]}, {"Citation": "Ide A.G., Baker N.H., Warren S.L. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 1939;42:891\u2013899."}, {"Citation": "Algire G.H., Chalkley H.W., Legallais F.Y., Park H.D. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl. Cancer Inst. 1945;6:73\u201385. doi: 10.1093/jnci/6.1.73.", "ArticleIdList": ["10.1093/jnci/6.1.73"]}, {"Citation": "Algire G.H. An adaptation of the transparent-chamber technique to the mouse. J. Natl. Cancer Inst. 1943;4:1\u201311."}, {"Citation": "Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971;285:1182\u20131186.", "ArticleIdList": ["4938153"]}, {"Citation": "Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987;235:442\u2013448. doi: 10.1126/science.2432664.", "ArticleIdList": ["10.1126/science.2432664", "2432664"]}, {"Citation": "Klagsbrun M., D\u2019Amore P.A. Regulators of angiogenesis. Annu. Rev. Physiol. 1991;53:217\u2013239. doi: 10.1146/annurev.ph.53.030191.001245.", "ArticleIdList": ["10.1146/annurev.ph.53.030191.001245", "1710435"]}, {"Citation": "Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983\u2013985. doi: 10.1126/science.6823562.", "ArticleIdList": ["10.1126/science.6823562", "6823562"]}, {"Citation": "Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989;161:851\u2013858. doi: 10.1016/0006-291X(89)92678-8.", "ArticleIdList": ["10.1016/0006-291X(89)92678-8", "2735925"]}, {"Citation": "Carmeliet P. VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology. 2005;69((Suppl. S3)):4\u201310. doi: 10.1159/000088478.", "ArticleIdList": ["10.1159/000088478", "16301830"]}, {"Citation": "Hicklin D.J., Ellis L.M. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J. Clin. Oncol. 2005;23:1011\u20131027. doi: 10.1200/JCO.2005.06.081.", "ArticleIdList": ["10.1200/JCO.2005.06.081", "15585754"]}, {"Citation": "Ferrara N., Carver-Moore K., Chen H., Dowd M. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439. doi: 10.1038/380439a0.", "ArticleIdList": ["10.1038/380439a0", "8602242"]}, {"Citation": "Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 1999;77:527\u2013543. doi: 10.1007/s001099900019.", "ArticleIdList": ["10.1007/s001099900019", "10494799"]}, {"Citation": "Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol.-Cell Physiol. 2001;280:C1358\u2013C1366. doi: 10.1152/ajpcell.2001.280.6.C1358.", "ArticleIdList": ["10.1152/ajpcell.2001.280.6.C1358", "11350730"]}, {"Citation": "Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997;18:4\u201325. doi: 10.1210/edrv.18.1.0287.", "ArticleIdList": ["10.1210/edrv.18.1.0287", "9034784"]}, {"Citation": "Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5:519\u2013524.", "ArticleIdList": ["2158038"]}, {"Citation": "Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., B\u00f6hlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992;187:1579\u20131586. doi: 10.1016/0006-291X(92)90483-2.", "ArticleIdList": ["10.1016/0006-291X(92)90483-2", "1417831"]}, {"Citation": "Paavonen K., Puolakkainen P., Jussila L., Jahkola T., Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 2000;156:1499\u20131504. doi: 10.1016/S0002-9440(10)65021-3.", "ArticleIdList": ["10.1016/S0002-9440(10)65021-3", "PMC1876915", "10793061"]}, {"Citation": "Kaipainen A., Korhonen J., Mustonen T., Van Hinsbergh V., Fang G.-H., Dumont D., Breitman M., Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA. 1995;92:3566\u20133570. doi: 10.1073/pnas.92.8.3566.", "ArticleIdList": ["10.1073/pnas.92.8.3566", "PMC42208", "7724599"]}, {"Citation": "Cao Y., Chen H., Zhou L., Chiang M.-K., Anand-Apte B., Weatherbee J.A., Wang Y., Fang F., Flanagan J.G., Tsang M.L.-S. Heterodimers of Placenta growth factor/vascular endothelial growth factor endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J. Biol. Chem. 1996;271:3154\u20133162. doi: 10.1074/jbc.271.6.3154.", "ArticleIdList": ["10.1074/jbc.271.6.3154", "8621715"]}, {"Citation": "DiSalvo J., Bayne M.L., Conn G., Kwok P.W., Trivedi P.G., Soderman D.D., Palisi T.M., Sullivan K.A., Thomas K.A. Purification and characterization of a naturally occurring vascular endothelial growth factor\u00b7 placenta growth factor heterodimer. J. Biol. Chem. 1995;270:7717\u20137723. doi: 10.1074/jbc.270.13.7717.", "ArticleIdList": ["10.1074/jbc.270.13.7717", "7706320"]}, {"Citation": "Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004;25:581\u2013611. doi: 10.1210/er.2003-0027.", "ArticleIdList": ["10.1210/er.2003-0027", "15294883"]}, {"Citation": "Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 1994;269:25646\u201325654. doi: 10.1016/S0021-9258(18)47298-5.", "ArticleIdList": ["10.1016/S0021-9258(18)47298-5", "7929268"]}, {"Citation": "Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin. Oncol. 2002;29:10\u201314. doi: 10.1053/sonc.2002.37264.", "ArticleIdList": ["10.1053/sonc.2002.37264", "12516033"]}, {"Citation": "Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996;56:2013\u20132016.", "ArticleIdList": ["8616842"]}, {"Citation": "Volm M., Koom\u00e4gi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer. 1997;74:64\u201368. doi: 10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I.", "ArticleIdList": ["10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I", "9036871"]}, {"Citation": "Ellis L., Takahashi Y., Fenoglio C., Cleary K., Bucana C., Evans D. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer. 1998;34:337\u2013340. doi: 10.1016/S0959-8049(97)10068-5.", "ArticleIdList": ["10.1016/S0959-8049(97)10068-5", "9640218"]}, {"Citation": "Tomisawa M., Tokunaga T., Oshika Y., Tsuchida T., Fukushima Y., Sato H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer. 1999;35:133\u2013137. doi: 10.1016/S0959-8049(98)00278-0.", "ArticleIdList": ["10.1016/S0959-8049(98)00278-0", "10211101"]}, {"Citation": "Sowter H., Corps A., Evans A., Clark D., Charnock-Jones D., Smith S. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Investig. A J. Tech. Methods Pathol. 1997;77:607\u2013614.", "ArticleIdList": ["9426398"]}, {"Citation": "Ferrer F.A., Miller L.J., Andrawis R.I., Kurtzman S.H., Albertsen P.C., Laudone V.P., Kreutzer D.L. Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In Situ and in Vitro Expression of VEGF by Human Prostate Cancer Cells. J. Urol. 1997;157:2329\u20132333. doi: 10.1016/S0022-5347(01)64775-X.", "ArticleIdList": ["10.1016/S0022-5347(01)64775-X", "9146665"]}, {"Citation": "Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig. 1995;95:1789. doi: 10.1172/JCI117857.", "ArticleIdList": ["10.1172/JCI117857", "PMC295707", "7535799"]}, {"Citation": "Dias S., Hattori K., Heissig B., Zhu Z., Wu Y., Witte L., Hicklin D.J., Tateno M., Bohlen P., Moore M.A. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. USA. 2001;98:10857\u201310862. doi: 10.1073/pnas.191117498.", "ArticleIdList": ["10.1073/pnas.191117498", "PMC58564", "11553814"]}, {"Citation": "Mazurakova A., Samec M., Koklesova L., Biringer K., Kudela E., Al-Ishaq R.K., Pec M., Giordano F.A., B\u00fcsselberg D., Kubatka P., et al. Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine-comprehensive effects of phytochemicals in primary, secondary and tertiary care. EPMA J. 2022;13:461\u2013486. doi: 10.1007/s13167-022-00288-z.", "ArticleIdList": ["10.1007/s13167-022-00288-z", "PMC9263437", "35821883"]}, {"Citation": "Bostwick D.G., Cooner W.H., Denis L., Jones G.W., Scardino P.T., Murphy G.P. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992;70:291\u2013301. doi: 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4.", "ArticleIdList": ["10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4", "1376199"]}, {"Citation": "Chokkalingam A.P., Nyr\u00e9n O., Johansson J.E., Gridley G., McLaughlin J.K., Adami H.O., Hsing A.W. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia. Cancer. 2003;98:1727\u20131734. doi: 10.1002/cncr.11710.", "ArticleIdList": ["10.1002/cncr.11710", "14534890"]}, {"Citation": "Schantz M.M., Bedner M., Long S.E., Molloy J.L., Murphy K.E., Porter B.J., Putzbach K., Rimmer C.A., Sander L.C., Sharpless K.E. Development of saw palmetto (Serenoa repens) fruit and extract standard reference materials. Anal. Bioanal. Chem. 2008;392:427\u2013438. doi: 10.1007/s00216-008-2297-0.", "ArticleIdList": ["10.1007/s00216-008-2297-0", "18677464"]}, {"Citation": "Gerber G.S., Fitzpatrick J.M. The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int. 2004;94:338\u2013344. doi: 10.1111/j.1464-410X.2004.04962.x.", "ArticleIdList": ["10.1111/j.1464-410X.2004.04962.x", "15291864"]}, {"Citation": "Bonnar-Pizzorno R.M., Littman A.J., Kestin M., White E. Saw palmetto supplement use and prostate cancer risk. Nutr. Cancer. 2006;55:21\u201327. doi: 10.1207/s15327914nc5501_3.", "ArticleIdList": ["10.1207/s15327914nc5501_3", "16965237"]}, {"Citation": "Bent S., Ko R. Commonly used herbal medicines in the United States: A review. Am. J. Med. 2004;116:478\u2013485. doi: 10.1016/j.amjmed.2003.10.036.", "ArticleIdList": ["10.1016/j.amjmed.2003.10.036", "15047038"]}, {"Citation": "Barnes P.M., Powell-Griner E., McFann K., Nahin R.L. Seminars in Integrative Medicine. WB Saunders; Philadelphia, PA, USA: 2004. Complementary and alternative medicine use among adults: United States, 2002; pp. 54\u201371.", "ArticleIdList": ["15188733"]}, {"Citation": "Bent S., Kane C., Shinohara K., Neuhaus J., Hudes E.S., Goldberg H., Avins A.L. Saw Palmetto for Benign Prostatic Hyperplasia. N. Engl. J. Med. 2006;354:557\u2013566. doi: 10.1056/NEJMoa053085.", "ArticleIdList": ["10.1056/NEJMoa053085", "16467543"]}, {"Citation": "Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review. Urology. 1996;48:12\u201320. doi: 10.1016/S0090-4295(96)00077-5.", "ArticleIdList": ["10.1016/S0090-4295(96)00077-5", "8693632"]}, {"Citation": "Goldmann W.H., Sharma A.L., Currier S.J., Johnston P.D., Rana A., Sharma C.P. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol. Int. 2001;25:1117\u20131124. doi: 10.1006/cbir.2001.0779.", "ArticleIdList": ["10.1006/cbir.2001.0779", "11913955"]}, {"Citation": "Iguchi K., Okumura N., Usui S., Sajiki H., Hirota K., Hirano K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate. 2001;47:59\u201365. doi: 10.1002/pros.1047.", "ArticleIdList": ["10.1002/pros.1047", "11304730"]}, {"Citation": "Hill B., Kyprianou N. Effect of permixon on human prostate cell growth: Lack of apoptotic action. Prostate. 2004;61:73\u201380. doi: 10.1002/pros.20088.", "ArticleIdList": ["10.1002/pros.20088", "15287095"]}, {"Citation": "Mann J. Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer. 2002;2:143\u2013148. doi: 10.1038/nrc723.", "ArticleIdList": ["10.1038/nrc723", "12635177"]}, {"Citation": "Katiyar C., Gupta A., Kanjilal S., Katiyar S. Drug discovery from plant sources: An integrated approach. Ayu. 2012;33:10\u201319. doi: 10.4103/0974-8520.100295.", "ArticleIdList": ["10.4103/0974-8520.100295", "PMC3456845", "23049178"]}, {"Citation": "Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991;83:757\u2013766. doi: 10.1093/jnci/83.11.757.", "ArticleIdList": ["10.1093/jnci/83.11.757", "2041050"]}, {"Citation": "Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 2008;12:306\u2013317. doi: 10.1016/j.cbpa.2008.03.016.", "ArticleIdList": ["10.1016/j.cbpa.2008.03.016", "18423384"]}, {"Citation": "Bohn T., McDougall G.J., Alegr\u00eda A., Alminger M., Arrigoni E., Aura A.-M., Brito C., Cilla A., El S.N., Karakaya S., et al. Mind the gap\u2014Deficits in our knowledge of aspects impacting the bioavailability of phytochemicals and their metabolites\u2014A position paper focusing on carotenoids and polyphenols. Mol. Nutr. Food Res. 2015;59:1307\u20131323. doi: 10.1002/mnfr.201400745.", "ArticleIdList": ["10.1002/mnfr.201400745", "PMC5033009", "25988374"]}, {"Citation": "Cordes E.H., Cordes E.H. Hallelujah Moments: Tales of Drug Discovery. Oxford University Press; Oxford, UK: 2020. 103C7The discovery of taxol: Wall, Horwitz, Holton.", "ArticleIdList": ["10.1093/oso/9780190080457.003.0007p.0"]}, {"Citation": "Barani M., Sangiovanni E., Angarano M., Rajizadeh M.A., Mehrabani M., Piazza S., Gangadharappa H.V., Pardakhty A., Mehrbani M., Dell\u2019Agli M., et al. Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature. Int. J. Nanomed. 2021;16:6983\u20137022. doi: 10.2147/IJN.S318416.", "ArticleIdList": ["10.2147/IJN.S318416", "PMC8527653", "34703224"]}, {"Citation": "Suvarna V., Gujar P., Murahari M. Complexation of phytochemicals with cyclodextrin derivatives\u2014An insight. Biomed. Pharmacother. 2017;88:1122\u20131144. doi: 10.1016/j.biopha.2017.01.157.", "ArticleIdList": ["10.1016/j.biopha.2017.01.157", "28208574"]}, {"Citation": "Li J., Wang Y., Yang C., Wang P., Oelschlager D.K., Zheng Y., Tian D.A., Grizzle W.E., Buchsbaum D.J., Wan M. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol. Pharmacol. 2009;76:81\u201390. doi: 10.1124/mol.109.054551.", "ArticleIdList": ["10.1124/mol.109.054551", "19395473"]}, {"Citation": "Rijo P., Matias D., Fernandes A., Sim\u00f5es M., Nicolai M., Reis C. Antimicrobial Plant Extracts Encapsulated into Polymeric Beads for Potential Application on the Skin. Polymers. 2014;6:479\u2013490. doi: 10.3390/polym6020479.", "ArticleIdList": ["10.3390/polym6020479"]}, {"Citation": "Date A.A., Hanes J., Ensign L.M. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J. Control Release. 2016;240:504\u2013526. doi: 10.1016/j.jconrel.2016.06.016.", "ArticleIdList": ["10.1016/j.jconrel.2016.06.016", "PMC5064878", "27292178"]}, {"Citation": "Xie J., Yang Z., Zhou C., Zhu J., Lee R.J., Teng L. Nanotechnology for the delivery of phytochemicals in cancer therapy. Biotechnol. Adv. 2016;34:343\u2013353. doi: 10.1016/j.biotechadv.2016.04.002.", "ArticleIdList": ["10.1016/j.biotechadv.2016.04.002", "27071534"]}, {"Citation": "Huang Q., Yu H., Ru Q. Bioavailability and Delivery of Nutraceuticals Using Nanotechnology. J. Food Sci. 2010;75:R50\u2013R57. doi: 10.1111/j.1750-3841.2009.01457.x.", "ArticleIdList": ["10.1111/j.1750-3841.2009.01457.x", "20492195"]}, {"Citation": "Chan J., Elkin E., Silva S., Broering J., Latini D., Carroll P. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology. 2005;66:1223\u20131228. doi: 10.1016/j.urology.2005.06.003.", "ArticleIdList": ["10.1016/j.urology.2005.06.003", "16360447"]}, {"Citation": "Lee M.M., Chang J.S., Jacobs B., Wrensch M.R. Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am. J. Public Health. 2002;92:1606\u20131609. doi: 10.2105/AJPH.92.10.1606.", "ArticleIdList": ["10.2105/AJPH.92.10.1606", "PMC1447292", "12356606"]}, {"Citation": "Trottier G., Bostrom P.J., Lawrentschuk N., Fleshner N.E. Nutraceuticals and prostate cancer prevention: A current review. Nat Rev Urol. 2010;7:21\u201330. doi: 10.1038/nrurol.2009.234.", "ArticleIdList": ["10.1038/nrurol.2009.234", "19997071"]}, {"Citation": "Curtis Nickel J., Shoskes D., Roehrborn C.G., Moyad M. Nutraceuticals in Prostate Disease: The Urologist\u2019s Role. Rev. Urol. 2008;10:192\u2013206.", "ArticleIdList": ["PMC2556486", "18836556"]}, {"Citation": "Coppens P., Da Silva M.F., Pettman S. European regulations on nutraceuticals, dietary supplements and functional foods: A framework based on safety. Toxicology. 2006;221:59\u201374. doi: 10.1016/j.tox.2005.12.022.", "ArticleIdList": ["10.1016/j.tox.2005.12.022", "16469424"]}, {"Citation": "Arora M., Sharma S., Baldi A. Comparative insight of regulatory guidelines for probiotics in USA, India and Malaysia: A critical review. Int. J. Biotechnol. Wellness Ind. 2013;2:51\u201364."}, {"Citation": "Nelson V.K., Pullaiah C.P., Saleem Ts M., Roychoudhury S., Chinnappan S., Vishnusai B., Ram Mani R., Birudala G., Bottu K.S. Natural Products as the Modulators of Oxidative Stress: An Herbal Approach in the Management of Prostate Cancer. Adv. Exp. Med. Biol. 2022;1391:161\u2013179. doi: 10.1007/978-3-031-12966-7_10.", "ArticleIdList": ["10.1007/978-3-031-12966-7_10", "36472822"]}, {"Citation": "Singh K., Bhori M., Kasu Y.A., Bhat G., Marar T. Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity\u2014Exploring the armoury of obscurity. Saudi Pharm. J. 2018;26:177\u2013190. doi: 10.1016/j.jsps.2017.12.013.", "ArticleIdList": ["10.1016/j.jsps.2017.12.013", "PMC6111235", "30166914"]}, {"Citation": "Anon Industry M.o.A.a.A., editor. National Agrofood Policy 2011\u20132020. 2016.  [(accessed on 30 December 2022)].  Malaysia. Available online:  https://ap.fftc.org.tw/article/1368."}, {"Citation": "Akarasereenont P., Datiles M.J.R., Lumlerdkij N., Yaakob H., Prieto J.M., Heinrich M. A South-East Asian Perspective on Ethnopharmacology. Ethnopharmacology. 2015:317\u2013332. doi: 10.1002/9781118930717.ch27.", "ArticleIdList": ["10.1002/9781118930717.ch27"]}, {"Citation": "Idris M.K.H., Hasham R., Ismail H.F. Bioassay-Guided extraction of andrographis paniculata for intervention of in-vitro prostate cancer progression in metabolic syndrome environment. Daru. 2022;30:253\u2013272. doi: 10.1007/s40199-021-00414-8.", "ArticleIdList": ["10.1007/s40199-021-00414-8", "PMC9715910", "35922691"]}, {"Citation": "Vetvicka V., Vannucci L. Biological properties of andrographolide, an active ingredient of Andrographis Paniculata: A narrative review. Ann. Transl. Med. 2021;9:1186. doi: 10.21037/atm-20-7830.", "ArticleIdList": ["10.21037/atm-20-7830", "PMC8350652", "34430627"]}, {"Citation": "Mir H., Kapur N., Singh R., Sonpavde G., Lillard J.W., Jr., Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016;15:819\u2013826. doi: 10.1080/15384101.2016.1148836.", "ArticleIdList": ["10.1080/15384101.2016.1148836", "PMC4845948", "27029529"]}, {"Citation": "Zhao F., He E.Q., Wang L., Liu K. Anti-tumor activities of andrographolide, a diterpene from Andrographis paniculata, by inducing apoptosis and inhibiting VEGF level. J. Asian Nat. Prod. Res. 2008;10:467\u2013473. doi: 10.1080/10286020801948334.", "ArticleIdList": ["10.1080/10286020801948334", "18464090"]}, {"Citation": "Chun J.Y., Tummala R., Nadiminty N., Lou W., Liu C., Yang J., Evans C.P., Zhou Q., Gao A.C. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010;1:868\u2013876. doi: 10.1177/1947601910383416.", "ArticleIdList": ["10.1177/1947601910383416", "PMC3063649", "21442031"]}, {"Citation": "Forestier-Rom\u00e1n I.S., L\u00f3pez-Rivas A., S\u00e1nchez-V\u00e1zquez M.M., Rohena-Rivera K., Nieves-Burgos G., Ortiz-Zuazaga H., Torres-Ramos C.A., Mart\u00ednez-Ferrer M. Andrographolide induces DNA damage in prostate cancer cells. Oncotarget. 2019;10:1085\u20131101. doi: 10.18632/oncotarget.26628.", "ArticleIdList": ["10.18632/oncotarget.26628", "PMC6383681", "30800220"]}, {"Citation": "Choi Y.-J., Fan M., Wedamulla N.E., Tang Y., Bae S.M., Hwang J.-Y., Kim E.-K. Inhibitory effects of Centella asiatica (L.) Urban on enlarged prostate through androgen receptor and PI3K/Akt signaling pathways. Food Funct. 2022;13:10235\u201310247. doi: 10.1039/D2FO00841F.", "ArticleIdList": ["10.1039/D2FO00841F", "36124918"]}, {"Citation": "Alafnan A., Hussain T., Rizvi S.M.D., Moin A., Alamri A. Prostate Apoptotic Induction and NF\u03baB Suppression by Dammarolic Acid: Mechanistic Insight into Onco-Therapeutic Action of an Aglycone Asiaticoside. Curr. Issues Mol. Biol. 2021;43:932\u2013940. doi: 10.3390/cimb43020066.", "ArticleIdList": ["10.3390/cimb43020066", "PMC8928952", "34449548"]}, {"Citation": "Hsu Y.L., Kuo P.L., Lin L.T., Lin C.C. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J. Pharmacol. Exp. Ther. 2005;313:333\u2013344. doi: 10.1124/jpet.104.078808.", "ArticleIdList": ["10.1124/jpet.104.078808", "15626723"]}, {"Citation": "Adtani P.N., Narasimhan M., Punnoose A.M., Kambalachenu H.R. Antifibrotic effect of Centella asiatica Linn and asiatic acid on arecoline-induced fibrosis in human buccal fibroblasts. J. Investig. Clin. Dent. 2017;8:e12208. doi: 10.1111/jicd.12208.", "ArticleIdList": ["10.1111/jicd.12208", "26840561"]}, {"Citation": "Hao Y., Huang J., Ma Y., Chen W., Fan Q., Sun X., Shao M., Cai H. Asiatic acid inhibits proliferation, migration and induces apoptosis by regulating Pdcd4 via the PI3K/Akt/mTOR/p70S6K signaling pathway in human colon carcinoma cells. Oncol. Lett. 2018;15:8223\u20138230. doi: 10.3892/ol.2018.8417.", "ArticleIdList": ["10.3892/ol.2018.8417", "PMC5950025", "29805556"]}, {"Citation": "Zulkipli I.N., Rajabalaya R., Idris A., Sulaiman N.A., David S.R. Clinacanthus nutans: A review on ethnomedicinal uses, chemical constituents and pharmacological properties. Pharm. Biol. 2017;55:1093\u20131113. doi: 10.1080/13880209.2017.1288749.", "ArticleIdList": ["10.1080/13880209.2017.1288749", "PMC6130650", "28198202"]}, {"Citation": "Teoh P.L., Cheng A.Y., Liau M., Lem F.F., Kaling G.P., Chua F.N., Cheong B.E. Chemical composition and cytotoxic properties of Clinacanthus nutans root extracts. Pharm. Biol. 2017;55:394\u2013401. doi: 10.1080/13880209.2016.1242145.", "ArticleIdList": ["10.1080/13880209.2016.1242145", "PMC6130766", "27931178"]}, {"Citation": "Ng P.Y., Chye S.M., Ng Ch H., Koh R.Y., Tiong Y.L., Pui L.P., Tan Y.H., Lim C.S., Ng Kh Y. Clinacanthus Nutans Hexane Extracts Induce Apoptosis Through a Caspase-Dependent Pathway in Human Cancer Cell Lines. Asian Pac. J. Cancer Prev. 2017;18:917\u2013926. doi: 10.22034/apjcp.2017.18.4.917.", "ArticleIdList": ["10.22034/apjcp.2017.18.4.917", "PMC5494240", "28545188"]}, {"Citation": "Md Toha Z., Haron N.H., Kamal N.N.S.N.M., Khairuddean M., Arsad H. Exploring Clinacanthus nutans leaf different solvent extracts on antiproliferative effects induced metastasis through apoptosis and cell cycle against MCF-7 human breast cancer cell lines. Future J. Pharm. Sci. 2022;8:49. doi: 10.1186/s43094-022-00437-1.", "ArticleIdList": ["10.1186/s43094-022-00437-1"]}, {"Citation": "Fazil F.N., Azzimi N.S., Yahaya B.H., Kamalaldin N.A., Zubairi S.I. Kinetics Extraction Modelling and Antiproliferative Activity of Clinacanthus nutans Water Extract. Sci. World J. 2016;2016:7370536. doi: 10.1155/2016/7370536.", "ArticleIdList": ["10.1155/2016/7370536", "PMC5221343", "28105464"]}, {"Citation": "George A., Henkel R. Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy. Andrologia. 2014;46:708\u2013721. doi: 10.1111/and.12214.", "ArticleIdList": ["10.1111/and.12214", "24386995"]}, {"Citation": "Tong K.L., Chan K.L., AbuBakar S., Low B.S., Ma H.Q., Wong P.F. The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells. PloS ONE. 2015;10:e0121752. doi: 10.1371/journal.pone.0121752.", "ArticleIdList": ["10.1371/journal.pone.0121752", "PMC4380335", "25826409"]}, {"Citation": "Berg C. Flora Malesiana precursor for the treatment of Moraceae 3: Ficus subgenus Ficus. Blumea-Biodivers. Evol. Biogeogr. Plants. 2003;48:529\u2013550. doi: 10.3767/000651903X489537.", "ArticleIdList": ["10.3767/000651903X489537"]}, {"Citation": "Burkill I.H., Haniff M. Malay Village Medicine: Prescriptions Collected by. University Press; Oxford, UK: 1930."}, {"Citation": "Abdullah N., Karsani S., Aminudin N. Effects of Ficus Deltoidea Extract on the Serum Protein Profile of Simultaneously Hypertensive Rats (SHR) J. Proteom. Bioinform. (JPB) 2008;2:143. doi: 10.4172/jpb.s1000111.", "ArticleIdList": ["10.4172/jpb.s1000111"]}, {"Citation": "Hadijah H., Normah A., Ahmad Tarmizi S., Aida M. Cholesterol lowering effect of mas cotek tea in hypercholesterolemic rats; Proceedings of the 2nd International Conference of East-West Perspective of Functional Food Science; Kuala Lumpur, Malaysia. 5\u20137 November 2007."}, {"Citation": "Bunawan H., Amin N.M., Bunawan S.N., Baharum S.N., Mohd Noor N. Ficus deltoidea Jack: A Review on Its Phytochemical and Pharmacological Importance. Evid.-Based Complement. Altern. Med. 2014;2014:902734. doi: 10.1155/2014/902734.", "ArticleIdList": ["10.1155/2014/902734", "PMC3977116", "24772185"]}, {"Citation": "Zakaria Z.A., Hussain M.K., Mohamad A.S., Abdullah F.C., Sulaiman M.R. Anti-Inflammatory Activity of the Aqueous Extract of Ficus Deltoidea. Biol. Res. Nurs. 2012;14:90\u201397. doi: 10.1177/1099800410395378.", "ArticleIdList": ["10.1177/1099800410395378", "21278166"]}, {"Citation": "Abdullah Z., Hussain K., Ismail Z., Ali R.M. Anti-inflammatory activity of standardised extracts of leaves of three varieties of Ficus deltoidea. Asian J. Pharm. Clin. Res. 2009;1:100\u2013105."}, {"Citation": "Uyub A.M., Nwachukwu I.N., Azlan A.A., Fariza S.S. In-vitro antibacterial activity and cytotoxicity of selected medicinal plant extracts from Penang Island Malaysia on metronidazole-resistant-Helicobacter pylori and some pathogenic bacteria. Ethnobot. Res. Appl. 2010;8:95\u2013106. doi: 10.17348/era.8.0.95-106.", "ArticleIdList": ["10.17348/era.8.0.95-106"]}, {"Citation": "Akhir N.A.M., Chua L.S., Majid F.A.A., Sarmidi M.R. Cytotoxicity of aqueous and ethanolic extracts of Ficus deltoidea on human ovarian carcinoma cell line. Br. J. Med. Med. Res. 2011;1:397\u2013409. doi: 10.9734/BJMMR/2011/507.", "ArticleIdList": ["10.9734/BJMMR/2011/507"]}, {"Citation": "Zhou Y., Liu Y.E., Cao J., Zeng G., Shen C., Li Y., Zhou M., Chen Y., Pu W., Potters L. Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth. Clin. Cancer Res. 2009;15:5161\u20135169. doi: 10.1158/1078-0432.CCR-09-0661.", "ArticleIdList": ["10.1158/1078-0432.CCR-09-0661", "PMC2752044", "19671865"]}, {"Citation": "Lin J.P., Yang J.S., Lin J.J., Lai K.C., Lu H.F., Ma C.Y., Sai-Chuen Wu R., Wu K.C., Chueh F.S., Gibson Wood W. Rutin inhibits human leukemia tumor growth in a murine xenograft model in vivo. Environ. Toxicol. 2012;27:480\u2013484. doi: 10.1002/tox.20662.", "ArticleIdList": ["10.1002/tox.20662", "21254320"]}, {"Citation": "Zheng S.-Y., Li Y., Jiang D., Zhao J., Ge J.-F. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549. Mol. Med. Rep. 2012;5:822\u2013826. doi: 10.3892/mmr.2011.726.", "ArticleIdList": ["10.3892/mmr.2011.726", "22200874"]}, {"Citation": "Guo Q., Tian X., Yang A., Zhou Y., Wu D., Wang Z. Orientin in Trollius chinensis Bunge inhibits proliferation of HeLa human cervical carcinoma cells by induction of apoptosis. Mon. F\u00fcr Chem.-Chem. Mon. 2014;145:229\u2013233. doi: 10.1007/s00706-013-1011-x.", "ArticleIdList": ["10.1007/s00706-013-1011-x"]}, {"Citation": "Chiang Y.-M., Kuo Y.-H. Novel Triterpenoids from the Aerial Roots of Ficus m icrocarpa. J. Org. Chem. 2002;67:7656\u20137661. doi: 10.1021/jo020262e.", "ArticleIdList": ["10.1021/jo020262e", "12398486"]}, {"Citation": "Chiang Y.-M., Chang J.-Y., Kuo C.-C., Chang C.-Y., Kuo Y.-H. Cytotoxic triterpenes from the aerial roots of Ficus microcarpa. Phytochemistry. 2005;66:495\u2013501. doi: 10.1016/j.phytochem.2004.12.026.", "ArticleIdList": ["10.1016/j.phytochem.2004.12.026", "15694457"]}, {"Citation": "Hanafi M.M.M., Afzan A., Yaakob H., Aziz R., Sarmidi M.R., Wolfender J.L., Prieto J.M. In Vitro Pro-apoptotic and Anti-migratory Effects of Ficus deltoidea L. Plant Extracts on the Human Prostate Cancer Cell Lines PC3. Front. Pharmacol. 2017;8:895. doi: 10.3389/fphar.2017.00895.", "ArticleIdList": ["10.3389/fphar.2017.00895", "PMC5736988", "29326585"]}, {"Citation": "Worawattananutai P., Itharat A., Ruangnoo S. In vitro antioxidant, anti-inflammatory, cytotoxic activities against prostate cancer of extracts from Hibiscus sabdariffa leaves. J. Med. Assoc. Thail. 2014;97((Suppl. S8)):S81\u2013S87.", "ArticleIdList": ["25518298"]}, {"Citation": "Chiu C.T., Chen J.H., Chou F.P., Lin H.H. Hibiscus sabdariffa Leaf Extract Inhibits Human Prostate Cancer Cell Invasion via Down-Regulation of Akt/NF-kB/MMP-9 Pathway. Nutrients. 2015;7:5065\u20135087. doi: 10.3390/nu7075065.", "ArticleIdList": ["10.3390/nu7075065", "PMC4516987", "26115086"]}, {"Citation": "Song B., Shen X., Tong C., Zhang S., Chen Q., Li Y., Li S. Gossypin: A flavonoid with diverse pharmacological effects. Chem. Biol. Drug Des. 2023;101:131\u2013137. doi: 10.1111/cbdd.14152.", "ArticleIdList": ["10.1111/cbdd.14152", "36198093"]}, {"Citation": "Chen D.L., Ma G.X., Yang E.L., Yang Y., Wang C.H., Sun Z.C., Liang H.Q., Xu X.D., Wei J.H. Cadinane-type sesquiterpenoid dimeric diastereomers hibisceusones A-C from infected stems of Hibiscus tiliaceus with cytotoxic activity against triple-negative breast cancer cells. Bioorganic Chem. 2022;127:105982. doi: 10.1016/j.bioorg.2022.105982.", "ArticleIdList": ["10.1016/j.bioorg.2022.105982", "35763902"]}, {"Citation": "Rasul H.O., Aziz B.K., Ghafour D.D., Kivrak A. Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: An in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction. Mol. Divers. 2022:1\u201324. doi: 10.1007/s11030-022-10556-9.", "ArticleIdList": ["10.1007/s11030-022-10556-9", "36318405"]}, {"Citation": "Laskar Y.B., Mazumder P.B., Talukdar A.D. Hibiscus sabdariffa anthocyanins are potential modulators of estrogen receptor alpha activity with favourable toxicology: A computational analysis using molecular docking, ADME/Tox prediction, 2D/3D QSAR and molecular dynamics simulation. J. Biomol. Struct. Dyn. 2023;41:611\u2013633. doi: 10.1080/07391102.2021.2009914.", "ArticleIdList": ["10.1080/07391102.2021.2009914", "34854367"]}, {"Citation": "Jamal J.A., Houghton P., Milligan S., Jantan I. The Oestrogenis and cytotoxic effects of the extracts of Labisia pumila var. alata and Labisia pumila var. pumila in vitro. Malays. J. Health Sci. 2003;1:53\u201360."}, {"Citation": "Ibrahim M.H., Jaafar H.Z. Photosynthetic capacity, photochemical efficiency and chlorophyll content of three varieties of Labisia pumila Benth. exposed to open field and greenhouse growing conditions. Acta Physiol. Plant. 2011;33:2179\u20132185. doi: 10.1007/s11738-011-0757-1.", "ArticleIdList": ["10.1007/s11738-011-0757-1"]}, {"Citation": "Al-Mekhlafi N.A., Shaari K., Abas F., Kneer R., Jeyaraj E.J., Stanslas J., Yamamoto N., Honda T., Lajis N.H. Alkenylresorcinols and cytotoxic activity of the constituents isolated from Labisia pumila. Phytochemistry. 2012;80:42\u201349. doi: 10.1016/j.phytochem.2012.04.008.", "ArticleIdList": ["10.1016/j.phytochem.2012.04.008", "22633846"]}, {"Citation": "Chua L.S., Lee S.Y., Abdullah N., Sarmidi M.R. Review on Labisia pumila (Kacip Fatimah): Bioactive phytochemicals and skin collagen synthesis promoting herb. Fitoterapia. 2012;83:1322\u20131335. doi: 10.1016/j.fitote.2012.04.002.", "ArticleIdList": ["10.1016/j.fitote.2012.04.002", "22521793"]}, {"Citation": "Chen H.M., Wu Y.C., Chia Y.C., Chang F.R., Hsu H.K., Hsieh Y.C., Chen C.C., Yuan S.S. Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate cancer cells. Cancer Lett. 2009;286:161\u2013171. doi: 10.1016/j.canlet.2009.05.040.", "ArticleIdList": ["10.1016/j.canlet.2009.05.040", "19589639"]}, {"Citation": "Albrecht D.S., Clubbs E.A., Ferruzzi M., Bomser J.A. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem.-Biol. Interact. 2008;171:89\u201395. doi: 10.1016/j.cbi.2007.09.001.", "ArticleIdList": ["10.1016/j.cbi.2007.09.001", "17931610"]}, {"Citation": "Pravettoni A., Mornati O., Martini P., Marino M., Colciago A., Celotti F., Motta M., Negri-Cesi P. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: Studies on the possible mechanism of action in DU145 cells. Mol. Cell. Endocrinol. 2007;263:46\u201354. doi: 10.1016/j.mce.2006.08.008.", "ArticleIdList": ["10.1016/j.mce.2006.08.008", "17023111"]}, {"Citation": "Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol. 2002;3:364\u2013373. doi: 10.1016/S1470-2045(02)00777-5.", "ArticleIdList": ["10.1016/S1470-2045(02)00777-5", "12107024"]}, {"Citation": "Hussain M., Banerjee M., Sarkar F.H., Djuric Z., Pollak M.N., Doerge D., Fontana J., Chinni S., Davis J., Forman J. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer. 2003;47:111\u2013117. doi: 10.1207/s15327914nc4702_1.", "ArticleIdList": ["10.1207/s15327914nc4702_1", "15087261"]}, {"Citation": "Mohd Hanafi M.M., Yaakob H., Sarmidi M.R., Aziz R., Prieto J.M. Marantodes pumilum L. plant extracts induce apoptosis, cell cycle arrest and inhibit cell migration and invasion on prostate cancer cell lines. Planta Med. 2016;82:P381. doi: 10.1055/s-0036-1596493.", "ArticleIdList": ["10.1055/s-0036-1596493"]}, {"Citation": "Hirasawa Y., Pagano I., Huang J., Sasaki Y., Murakami K., Rosser C.J., Furuya H. Case Study of Noni Extract in Men with Very Low-Risk or Low-Risk Prostate Cancer. Hawaii J. Health Soc. Welf. 2021;80:242\u2013250.", "ArticleIdList": ["PMC8504295", "34661119"]}, {"Citation": "Akihisa T., Matsumoto K., Tokuda H., Yasukawa K., Seino K., Nakamoto K., Kuninaga H., Suzuki T., Kimura Y. Anti-inflammatory and potential cancer chemopreventive constituents of the fruits of Morinda citrifolia (Noni) J. Nat. Prod. 2007;70:754\u2013757. doi: 10.1021/np068065o.", "ArticleIdList": ["10.1021/np068065o", "17480098"]}, {"Citation": "Liu G., Bode A., Ma W.Y., Sang S., Ho C.T., Dong Z. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. Cancer Res. 2001;61:5749\u20135756.", "ArticleIdList": ["11479211"]}, {"Citation": "Hiwasa T., Arase Y., Chen Z., Kita K., Umezawa K., Ito H., Suzuki N. Stimulation of ultraviolet-induced apoptosis of human fibroblast UVr-1 cells by tyrosine kinase inhibitors. FEBS Lett. 1999;444:173\u2013176. doi: 10.1016/S0014-5793(99)00057-5.", "ArticleIdList": ["10.1016/S0014-5793(99)00057-5", "10050753"]}, {"Citation": "Liu X.L., Zhang L., Fu X.L., Chen K., Qian B.C. Effect of scopoletin on PC3 cell proliferation and apoptosis. Acta Pharmacol. Sin. 2001;22:929\u2013933.", "ArticleIdList": ["11749777"]}, {"Citation": "Carastro L.M., Vallebuona E.J., Cordova R., Gannon A.N., Kim S.J., Costello C.M., Declet-Bauzo R.A., Kumar N., Park J.Y. Polyphenon E Effects on Gene Expression in PC-3 Prostate Cancer Cells. Int. J. Mol. Sci. 2022;23:14328. doi: 10.3390/ijms232214328.", "ArticleIdList": ["10.3390/ijms232214328", "PMC9697490", "36430806"]}, {"Citation": "Patel K., Patel D.K. Therapeutic effectiveness of sinensetin against cancer and other human complications: A review of biological potential and pharmacological activities. Cardiovasc. Hematol. Disord. Drug Targets. 2022;22:144\u2013154. doi: 10.2174/1871529X23666221207121955.", "ArticleIdList": ["10.2174/1871529X23666221207121955", "36503465"]}, {"Citation": "Suhaimi S.H., Hasham R., Hafiz Idris M.K., Ismail H.F., Mohd Ariffin N.H., Abdul Majid F.A. Optimization of Ultrasound-Assisted Extraction Conditions Followed by Solid Phase Extraction Fractionation from Orthosiphon stamineus Benth (Lamiace) Leaves for Antiproliferative Effect on Prostate Cancer Cells. Molecules. 2019;24:4183. doi: 10.3390/molecules24224183.", "ArticleIdList": ["10.3390/molecules24224183", "PMC6891422", "31752230"]}, {"Citation": "Al-Suede F.S., Khadeer Ahamed M.B., Abdul Majid A.S., Baharetha H.M., Hassan L.E., Kadir M.O., Nassar Z.D., Abdul Majid A.M. Optimization of Cat\u2019s Whiskers Tea (Orthosiphon stamineus) Using Supercritical Carbon Dioxide and Selective Chemotherapeutic Potential against Prostate Cancer Cells. Evid.-Based Complement. Altern. Med. Ecam. 2014;2014:396016. doi: 10.1155/2014/396016.", "ArticleIdList": ["10.1155/2014/396016", "PMC4170752", "25276215"]}, {"Citation": "Manthey J.A., Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 2002;50:5837\u20135843. doi: 10.1021/jf020121d.", "ArticleIdList": ["10.1021/jf020121d", "12358447"]}, {"Citation": "Tang Y.Q., Jaganath I., Manikam R., Sekaran S.D. Phyllanthus Suppresses Prostate Cancer Cell, PC-3, Proliferation and Induces Apoptosis through Multiple Signalling Pathways (MAPKs, PI3K/Akt, NF\u03baB, and Hypoxia) Evid.-Based Complement. Altern. Med. Ecam. 2013;2013:609581. doi: 10.1155/2013/609581.", "ArticleIdList": ["10.1155/2013/609581", "PMC3652183", "23690850"]}, {"Citation": "Tang Y.Q., Jaganath I.B., Sekaran S.D. Phyllanthus spp. induces selective growth inhibition of PC-3 and MeWo human cancer cells through modulation of cell cycle and induction of apoptosis. PloS ONE. 2010;5:e12644. doi: 10.1371/journal.pone.0012644.", "ArticleIdList": ["10.1371/journal.pone.0012644", "PMC2935893", "20838625"]}, {"Citation": "Mohd Hanafi M.  Ph.D. Thesis. University College London; London, UK: 2017.  [(accessed on 30 December 2022)]. In Vitro Pro-Apoptotic and Anti-Migratory Effects of Marantodes Pumilum (Blume) Kuntze and Ficus Deltoidea L. Extracts on Prostate Cancer Cell Lines. Available online:  https://discovery.ucl.ac.uk/id/eprint/1560225/"}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "12", "Day": "31"}, {"Year": "2023", "Month": "2", "Day": "7"}, {"Year": "2023", "Month": "2", "Day": "8"}, {"Year": "2023", "Month": "2", "Day": "24", "Hour": "9", "Minute": "33"}, {"Year": "2023", "Month": "2", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "25", "Hour": "6", "Minute": "1"}, {"Year": "2023", "Month": "2", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["36826044", "PMC9954984", "10.3390/cimb45020099", "cimb45020099"]}}], "PubmedBookArticle": []}